loading page

Acute left ventricular dysfunction following gemtuzumab ozogamicin in two children with AML
  • +3
  • Kevin McNerney,
  • Katelyn Oranges,
  • Alix Seif,
  • Benjamin Oshrine,
  • Kelly Getz,
  • Richard Aplenc
Kevin McNerney
The Children's Hospital of Philadelphia
Author Profile
Katelyn Oranges
The Children's Hospital of Philadelphia
Author Profile
Alix Seif
Children's Hospital of Philadelphia
Author Profile
Benjamin Oshrine
Johns Hopkins All Children's Hospital
Author Profile
Kelly Getz
The Children's Hospital of Philadelphia
Author Profile
Richard Aplenc
The Children’s Hospital of Philadelphia
Author Profile

Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+ acute myeloid leukemia (AML). Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome (SOS). Cardiotoxicity has not been a commonly described adverse event. We describe two pediatric patients with relapsed/refractory AML who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.